A 10% increase in step rate improves running kinematics and clinical outcomes in runners with patellofemoral pain at 4 weeks and 3 months

Key points

1. 01A single 10-minute session with an audible metronome was used to increase step rate by 10%; runners then self-monitored with a GPS smartwatch
2. 02Pain scores dropped from an average of 6.2/10 at baseline to 1.0/10 at 4 weeks and 0.3/10 at 3 months
3. 03Frontal-plane hip and pelvic kinematics improved significantly and the gains held at 3-month follow-up
4. 04Only runners confirmed to have aberrant hip and pelvis kinematics at baseline were enrolled, which may explain the larger improvements compared with previous studies
5. 05The approach can be self-administered outside a clinical lab, requiring minimal supervision

How it was conducted

Design

Prospective case series (Level of evidence 4); registered clinical trial NCT03067545

Participants

12 runners with confirmed patellofemoral pain AND aberrant frontal-plane hip and/or pelvis kinematics on 3D gait analysis (4 male, 8 female; mean age 39.9 years)

Intervention

Single 10-minute session increasing step rate by 10% using an audible metronome; self-monitored thereafter with GPS smartwatch and metronome app

Follow-up

Baseline, 4 weeks post-retraining, and 3 months post-retraining

Primary outcomes

Peak contralateral pelvic drop, hip adduction, knee flexion during stance; pain (NRS 0-10); Lower Extremity Functional Scale (LEFS); weekly running volume; longest pain-free run

What they found

• Step rate increased by an average of 11.2% at 4 weeks (MD 18.6 steps/min, 95% CI 11.97-25.23) and 9.2% at 3 months (MD 15.1 steps/min, 95% CI 10.64-19.57)
• Contralateral pelvic drop reduced by 3.12 degrees at 4 weeks (95% CI 1.88-4.37 deg) and 2.7 degrees at 3 months (95% CI 1.4-4.1 deg); p<.01
• Hip adduction reduced by 3.99 degrees at 4 weeks (95% CI 2.01-5.96 deg) and 2.8 degrees at 3 months (95% CI 0.4-5.4 deg); p<.01
• Peak knee flexion during stance reduced by 4.10 degrees at 4 weeks (95% CI 0.04-8.15 deg) and 4.15 degrees at 3 months (95% CI 0.81-7.48 deg); p<.01
• Worst pain (NRS) dropped from mean 6.2 at baseline to 1.0 at 4 weeks and 0.3 at 3 months (chi-square 21.38, p<.01), exceeding the minimal clinically important difference of 1.2 points
• LEFS improved from 62.3 at baseline to 76.6 at 4 weeks and 79.7 at 3 months (chi-square 22.29, p=.01), a 17.4-point improvement at 3 months exceeding the MCID of 9 points
• Total weekly running volume increased by MD 13.78 km (95% CI 4.62-22.93 km); longest pain-free run increased by MD 6.84 km (95% CI 3.05-10.62 km)
• Hip internal rotation showed no significant change at any time point (p=.93)

Limitations

• No control group, making it impossible to fully separate intervention effects from natural history or regression to the mean
• Very small sample (n=12), limiting statistical power to detect differences between follow-up time points
• Participants were highly selected - only those with confirmed aberrant kinematics were included, so results may not generalise to all runners with patellofemoral pain
• Training volume was not controlled after 4 weeks; one participant sustained a tibial stress fracture possibly related to a sudden training increase rather than the intervention itself

Why it matters

For patients

Runners with kneecap pain who have abnormal hip movement patterns may achieve meaningful pain relief and return to longer runs through a simple step-rate change they can manage themselves with a free metronome app and smartwatch.

For clinicians

Gait analysis to screen for aberrant frontal-plane kinematics before prescribing step-rate retraining appears important - enrolling only biomechanical responders may explain the larger clinical gains seen here compared with unselected cohorts.

For readers

This small uncontrolled case series provides promising early evidence that a one-session, self-administered cadence intervention can improve both mechanics and outcomes in a selected subset of runners with patellofemoral pain, but randomised controlled trials are needed to confirm efficacy.